Pioglitazone and Metformin Hydrochloride
Brand Names: Actoplus Met
Methodology & AI Transparency ⓘ
Pioglitazone and Metformin Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use Pioglitazone and metformin hydrochloride tablets is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis.
- 2 Real-world patient consensus: Real-world cohort score of 93% across 17 de-identified Pioglitazone and Metformin Hydrochloride entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $16.94 mail/discount cash up to $41.50 uninsured retail (federal NADAC $0.2083).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Pioglitazone and Metformin Hydrochloride include headache (9.5%), diarrhea (8.2%), peripheral edema (2.8%).
Ask our AI Specialists anything about Pioglitazone and Metformin Hydrochloride
Pioglitazone and Metformin Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use Pioglitazone and metformin hydrochloride tablets is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis. Pioglitazone and metformin hydrochloride tablets are a thiazolidinedione and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate.
12.1 Mechanism of Action Pioglitazone and metformin hydrochloride tablets combines two antihyperglycemic agents: pioglitazone and metformin. Pioglitazone Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ).
Pharmacokinetic profiling of Pioglitazone and Metformin Hydrochloride demonstrates an elimination half-life of Mean elimination half-life of 4 to 15 hours across adult Pioglitazone and Metformin Hydrochloride dosing with Oral fraction absorbed ranges from 50% to 62% (Pioglitazone and Metformin Hydrochloride 850) systemic bioavailability; clearance proceeds via biotransformed through cyp2c8 pathways with mixed urinary/fecal clearance, reaching clinical onset within oral tmax achieved within 2 to 3 hours following pioglitazone and metformin hydrochloride ingestion.
Titration schedules for Pioglitazone and Metformin Hydrochloride (850 mg/1 / 15 mg/1 Tablet → 500 mg/1 / 15 mg/1 Tablet → 15 mg/1 / 850 mg/1 Tablet, Film Coated → 15 mg/1 / 500 mg/1 Tablet → 15 mg/1 / 850 mg/1 Tablet) require excluding pioglitazone and metformin hydrochloride tablets are contraindicated in patients with:; established nyha class iii or iv heart failure at the time of pioglitazone and metformin hydrochloride tablets initiation .; severe renal impairment (egfr below 30 ml/min) .; real-world patient logs highlight headache (9.5% of reports), diarrhea (8.2% of reports), nausea (8% of reports) alongside a 93.00% Worth-It consensus.
Chronic enzyme induction shortens Pioglitazone and Metformin Hydrochloride persistence in plasma and reduces steady-state exposure.
Systemic bioavailability and half-life of Pioglitazone and Metformin Hydrochloride respond to strong CYP2C8 enzymatic inhibition or induction.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Pioglitazone and metformin hydrochloride tablets are contraindicated in patients with:
- Established NYHA Class III or IV heart failure at the time of pioglitazone and metformin hydrochloride tablets initiation .
- Severe renal impairment (eGFR below 30 mL/min) .
Logged Side-Effect Incidence (17 Reports)
Pioglitazone and Metformin Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pioglitazone and Metformin Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical... The Journal of clinical endocrinology and metabolism • 2009-04-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 19158194 ↗ |
| Can This Approach Help? Inside the Latest Research on Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Compared with placebo, adjusted mean (95% CI) changes from baseline in HbA1c level at week 76 were -0.59% (-0.79% to -0.40%; P < 0.001) for empagliflozin 10 mg (-6.5 [-8.6 to -4.4] mmol/mol) and -0.69% (-0.88% to -0.50%; P <... Clinical therapeutics • 2015-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 26138864 ↗ |
| Can This Approach Help? Inside the Latest Research on Association of pioglitazone treatment with decreased bone mineral density in Pioglitazone treatment was followed by decreased lumbar and hip BMD and decreased measures of bone turnover in a premenopausal study population relatively protected from bone mineral loss. The Journal of clinical endocrinology and metabolism • 2008-05-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 18285411 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of once-weekly glucagon-like peptide 1 receptor agonist Albiglutide 30 mg administered once weekly as an add-on to pioglitazone (with or without metformin) provided effective and durable glucose lowering and was generally well tolerated. Diabetes, obesity & metabolism • 2014-12-15 • Phase III Randomized Trial | N = 155 | 88/100 | PMID 25155146 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of pioglitazone and its combination with statins in coronary artery Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone. Canadian journal of physiology and pharmacology • 2007-06-15 • Randomized Controlled Trial | N = 83 | 88/100 | PMID 17823625 ↗ |
Pioglitazone and Metformin Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2083/unit (~$6.25/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $41.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $16.94 / mo | View logs ↓ |
Pioglitazone and Metformin Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pioglitazone and Metformin Hydrochloride RxNorm Concept ID | 861822 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2083 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $41.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $16.94 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Pioglitazone and Metformin Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Deterministic Pioglitazone and Metformin Hydrochloride reference combining NIH RxNorm (861822), Medicaid NADAC ($0.2083/unit), and anonymous cohort outcomes (93% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Pioglitazone and Metformin Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.